Tomas Leanderson appointed new President & CEO for Active Biotech

LUND, SWEDEN–(EMWNews – July 23, 2008) – Sven Andréasson has notified the Board of his

wish to resign from the

position as President & CEO of Active Biotech AB.

Sven Andréasson has been the company’s CEO since 1999 and under his

leadership Active Biotech has been transformed from a combined

vaccine and research company into a company focused on development of

novel pharmaceuticals for treatment of cancer and autoimmune

diseases.

The Board of Active Biotech AB has today decided to appoint Tomas

Leanderson to become the new President & CEO. Tomas Leanderson has

been the CSO for Active Biotech since 1999 (www.activebiotech.com).

Sven Andréasson will remain as CEO until September 1st 2008.

For further information please contact;



Mats Arnhög

Chairman of the Board

Telephone:  +46 8 545 037 70

Mobile: +46 705 91 50 96

Lund, July 23, 2008

About Active Biotech

Active Biotech AB (OMX NORDIC: ACTI), headquartered in Sweden, is a

biotechnology company with R&D focus on autoimmune/inflammatory

diseases and cancer. Projects in pivotal phase are laquinimod, an

orally administered small molecule with unique immunomodulatory

properties for the treatment of multiple sclerosis, as well as ANYARA

for use in cancer targeted therapy, primarily renal cancer. Further

key projects in clinical development comprise the three orally

administered compounds TASQ for prostate cancer, 57-57 for SLE and

RhuDex® for RA. Please visit www.activebiotech.com for more

information.

Active Biotech is required under the Securities Markets Act to make

the information in this press release public. The information was

submitted for publication at 8:30 a.m. CET on July 23, 2008.

Active Biotech AB

PO Box 724, 220 07 Lund

Sweden

Tel +46 (0)46-19 20 00

Fax +46 (0)46-19 20 50

Copyright © Hugin AS 2008. All rights reserved.